Astrazeneca Korea Co. Ltd. will pull its blockbuster diabetes drug, Forxiga (dapagliflozin), from the South Korean market, a company official confirmed to BioWorld, citing “multiple factors” like ...
Consumer hopes for a version of AstraZeneca's blockbuster diabetes drug Forxiga that doesn't hit hip pockets as hard have been dented by a court win to the pharma giant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results